Avidity Biosciences Inks Global Licensing And Research Collaboration Deal With Bristol Myers Squibb
(RTTNews) - Biopharmaceutical company Avidity Biosciences, Inc. (RNA) announced Tuesday a global licensing and research collaboration with Bristol Myers Squibb (BMY) focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.
Avidity will receive $100 million up front with the potential to receive up to $2.2 billion in milestone payments and up to low double-digit royalties. Bristol Myers Squibb will fund all future clinical development, regulatory and commercialization activities coming from this collaboration
The collaboration is designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. This strategic collaboration broadens the existing relationship with Bristol Myers Squibb.
I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study
Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation
Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers
Bristol-Myers Squibb Guides FY24 Adj. EPS Above Estimates As Q4 Results Top Estimates - Update
Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal
Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash
Bristol-Myers Squibb Boosts FY23 Adj. EPS Outlook As Q3 Adj. EPS Tops Estimates
